Australia - English - Department of Health (Therapeutic Goods Administration)

sumatriptan succinate -

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - sumatriptan succinate - film coated tablet - 50 milligram - selective serotonin (5ht1) agonists

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - sumatriptan succinate - film coated tablet - 100 milligram - selective serotonin (5ht1) agonists

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 0.25 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 0.5 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 1 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 2.51 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - fludrocortisone acetate 0.1 mg - corticosteroids for systemic use

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - pigs - for active immunisation of pigs from 7 weeks of age onwards to prevent mortality and reduce infection and disease caused by classical swine fever virus (csfv).onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv.onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - modified live porcine respiratory and reproductive syndrome virus - immunologicals for suidae, live viral vaccines - pigs - for active immunisation of clinically healthy pigs from 1 day of age in a porcine respiratory and reproductive syndrome (prrs) virus contaminated environment, to reduce viraemia and nasal shedding caused by infection with european strains of prrs virus (genotype 1).fattening pigs: in addition, vaccination of seronegative 1-day-old piglets was demonstrated to significantly reduce lung lesions against challenge administered at 26 weeks post vaccination. vaccination of seronegative 2-week-old piglets was demonstrated to significantly reduce lung lesions and oral shedding against challenge administered at 28 days and at 16 weeks post-vaccination.gilts and sows: in addition, pre-pregnancy vaccination of clinically healthy gilts and sows, either seropositive or seronegative, was demonstrated to reduce the transplacental infection caused by prrs virus during the third trimester of pregnancy, and to reduce the associated negative impact on reproductive performance (reduction of the occurrence of stillbirths, of piglet viraemia at birth and at weaning, of lung lesions and of viral load in lungs in piglets at weaning).